Research map: Lonvoguran ziclumeran: a CRISPR-CAS9-based gene therapy for the treatment of hereditary angioedema

Back to the article

Papers in this map

  1. Adeno-associated virus as a delivery vector for gene therapy of human diseases · Jiang-Hui Wang · 2024 · 834 citations · Cited by this paper
  2. Advancements in longevity pharmacology research – are we finally seeing clinical progression? · 2026 · Related
  3. Hereditary Angioedema: New Findings Concerning Symptoms, Affected Organs, and Course · Konrad Bork · 2006 · 759 citations · Cited by this paper
  4. Placebo-controlled trial of pharmacokinetics, pharmacodynamics and tolerability of KL130008 capsule in patients with rheumatoid arthritis · 2025 · Related
  5. Chromothripsis as an on-target consequence of CRISPR–Cas9 genome editing · Mitchell L. Leibowitz · 2021 · 597 citations · Cited by this paper
  6. Assessing the clinical development of zerlasiran, a small-interfering RNA for elevated lipoprotein(a) · 2025 · Related
  7. Engineered ionizable lipid nanoparticles for targeted delivery of RNA therapeutics into different types of cells in the liver · M. Kim · 2021 · 395 citations · Cited by this paper
  8. The journey of targeted drug conjugates in solid tumors: moving beyond antibody drug conjugates · 2026 · Related
  9. Reformulating lipid nanoparticles for organ-targeted mRNA accumulation and translation · Kexin Su · 2024 · 259 citations · Cited by this paper
  10. Cognitive-enhancing drugs in Phase II clinical trials for Alzheimer’s disease: emerging therapeutic candidates · 2026 · Related
  11. Oral once-daily berotralstat for the prevention of hereditary angioedema attacks: A randomized, double-blind, placebo-controlled phase 3 trial · Bruce L. Zuraw · 2020 · 174 citations · Cited by this paper
  12. Assessing the clinical progress of muvalaplin for reducing lipoprotein(a) · 2025 · Related
  13. Patient-reported burden of hereditary angioedema: findings from a patient survey in the United States · Aleena Banerji · 2020 · 172 citations · Cited by this paper
  14. Menin inhibitors for adult acute myeloid leukemia: 2025 update · 2025 · Related
  15. A focused parameter update: Hereditary angioedema, acquired C1 inhibitor deficiency, and angiotensin-converting enzyme inhibitor–associated angioedema · Bruce L. Zuraw · 2013 · 169 citations · Cited by this paper
  16. Consideration of the use of nalbuphine in idiopathic pulmonary fibrosis-associated cough: to cough or not to cough so much? · 2026 · Related
  17. HAE Pathophysiology and Underlying Mechanisms · Bruce L. Zuraw · 2016 · 168 citations · Cited by this paper
  18. Experimental JAK inhibitors: the current, present, and future in graft-versus-host disease management? · 2026 · Related
  19. Economic costs associated with acute attacks and long-term management of hereditary angioedema · David A. Wilson · 2010 · 159 citations · Cited by this paper
  20. Monoclonal antibodies in the management of hereditary angioedema · 2026 · Related
  21. Immunogenicity of Recombinant Adeno-Associated Virus (AAV) Vectors for Gene Transfer · Motahareh Arjomandnejad · 2023 · 155 citations · Cited by this paper
  22. Hereditary angioedema: Epidemiology and burden of disease · William R. Lumry · 2020 · 146 citations · Cited by this paper
  23. Hereditary Angioedema with Normal C1 Inhibitor: Clinical Symptoms and Course · Konrad Bork · 2007 · 138 citations · Cited by this paper
  24. Hereditary Angioedema: Diagnosis, Clinical Implications, and Pathophysiology · Evan S. Sinnathamby · 2023 · 134 citations · Cited by this paper
  25. Genetics of Hereditary Angioedema Revisited · Anastasios E. Germenis · 2016 · 131 citations · Cited by this paper
  26. Efficacy and safety of garadacimab, a factor XIIa inhibitor for hereditary angioedema prevention (VANGUARD): a global, multicentre, randomised, double-blind, placebo-controlled, phase 3 trial · Timothy Craig · 2023 · 126 citations · Cited by this paper
  27. Assessment and management of disease burden and quality of life in patients with hereditary angioedema: a consensus report · Konrad Bork · 2021 · 113 citations · Cited by this paper
  28. Pathogenesis of Hereditary Angioedema · Allen P. Kaplan · 2017 · 104 citations · Cited by this paper
  29. Assembly and activation of HK-PK complex on endothelial cells results in bradykinin liberation and NO formation · Yongqiang Zhao · 2001 · 96 citations · Cited by this paper
  30. Bradykinin B2 receptor knockout mice are protected from thrombosis by increased nitric oxide and prostacyclin · Zia Shariat‐Madar · 2006 · 93 citations · Cited by this paper
  31. Safer and efficient base editing and prime editing via ribonucleoproteins delivered through optimized lipid-nanoparticle formulations · Rafał Hołubowicz · 2024 · 93 citations · Cited by this paper
  32. Reduced thrombosis in Klkb1−/− mice is mediated by increased Mas receptor, prostacyclin, Sirt1, and KLF4 and decreased tissue factor · Evi X. Stavrou · 2014 · 91 citations · Cited by this paper
  33. Treatment of Hereditary Angioedema · Teresa Caballero · 2021 · 86 citations · Cited by this paper
  34. Angiotensin 1-7 and Mas decrease thrombosis in Bdkrb2−/− mice by increasing NO and prostacyclin to reduce platelet spreading and glycoprotein VI activation · Chao Fang · 2013 · 85 citations · Cited by this paper
  35. Efficacy and Safety of Donidalorsen for Hereditary Angioedema · Marc A. Riedl · 2024 · 77 citations · Cited by this paper
  36. Inhibition of Prekallikrein for Hereditary Angioedema · Lauré M. Fijen · 2022 · 74 citations · Cited by this paper
  37. Hereditary angioedema: a bradykinin-mediated swelling disorder · Jenny Björkqvist · 2013 · 70 citations · Cited by this paper
  38. Oral Sebetralstat for On-Demand Treatment of Hereditary Angioedema Attacks · Marc A. Riedl · 2024 · 68 citations · Cited by this paper
  39. Hereditary Angioedema: The Economics of Treatment of an Orphan Disease · William R. Lumry · 2018 · 57 citations · Cited by this paper

Source: OpenAlex (CC0)